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Background: Dysregulation of microRNA (miRNA) expression has been implicated in molecular genetic events
leading to the progression and development of atherosclerosis. We hypothesized that miRNA expression profiles
differ between baboons with low and high serum low-density lipoprotein cholesterol (LDL-C) concentrations in
response to diet, and that a subset of these miRNAs regulate genes relevant to dyslipidemia and risk of
atherosclerosis.
Results: Using Next Generation Illumina sequencing methods, we sequenced hepatic small RNA libraries from
baboons differing in their LDL-C response to a high-cholesterol, high-fat (HCHF) challenge diet (low LDL-C, n = 3;
high LDL-C, n = 3), resulting in 517 baboon miRNAs: 490 were identical to human miRNAs and 27 were novel. We
compared miRNA expression profiles from liver biopsies collected before and after the challenge diet and observed
that HCHF diet elicited expression of more miRNAs compared to baseline (chow) diet for both low and high LDL-C
baboons. Eighteen miRNAs exhibited differential expression in response to HCHF diet in high LDL-C baboons
compared to 10 miRNAs in low LDL-C baboons. We used TargetScan/Base tools to predict putative miRNA targets;
miRNAs expressed in high LDL-C baboons had significantly more gene targets than miRNAs expressed in low
LDL-C responders. Further, we identified miRNA isomers and other non-coding RNAs that were differentially
expressed in response to the challenge diet in both high LDL-C and low LDL-C baboons.
Conclusions: We sequenced and annotated baboon liver miRNAs from low LDL-C and high LDL-C responders
using high coverage Next Gen sequencing methods, determined expression changes in response to a HCHF diet
challenge, and predicted target genes regulated by the differentially expressed miRNAs. The identified miRNAs will
enrich the database for non-coding small RNAs including the extent of variation in these sequences. Further, we
identified other small non-coding RNAs differentially expressed in response to diet. Our discovery of differentially
expressed baboon miRNAs in response to a HCHF diet challenge that differ by LDL-C phenotype is a fundamental
step in understating the role of non-coding RNAs in dyslipidemia.Background
Cardiovascular disease (CVD), a leading cause of mortal-
ity in the United States, is commonly due to the develop-
ment of atherosclerosis [1]. Atherosclerosis is a chronic
inflammatory disease affecting medium and large arter-
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reproduction in any medium, provided the orgenotype and environmental factors including diet,
which influences dyslipidemia. Clinical and epidemio-
logical studies indicate that atherosclerosis is positively
correlated with serum LDL-C and inversely correlated
with high-density lipoprotein cholesterol (HDL-C) [2-5],
demonstrating that increased levels of serum LDL-C is a
major risk factor for atherosclerosis [6]. However, the
exact mechanism by which LDL-C promotes atheroscler-
osis remains an active aspect for research. Early studies
by Brown and Goldstein [6] demonstrated that oxidized
LDL-C (ox-LDL-C) is a prerequisite for initiation of ath-
erosclerotic lesions, leading to the development ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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studies have confirmed that ox-LDL-C is an essential
atherosclerotic risk factor, triggering arterial cellular
modification [9-11]. Lowering LDL-C reduces the risk
for atherosclerosis in humans, and modification of diet
and lifestyle, and administration of drugs is a major strat-
egy to control CVD [12].
Apart from the physiological characteristics, under-
standing the genetic mechanisms underlying dyslipide-
mia and subsequent development of atherosclerosis is
fundamental to therapeutic interventions. Many genetic
factors influencing risk factors for atherosclerosis have
been identified [13], including genes underlying the vul-
nerability of arterial intimal layer to ox-LDL-C [10,14].
The expression of genes important for development of
atherosclerosis is modulated by a variety of elements, in-
cluding microRNAs (miRNAs).
miRNAs are small endogenous non-coding RNAs that
are evolutionarily conserved across many species and
the biogenesis of miRNAs has been described [15,16].
miRNAs down-regulate gene expression by translational
repression [15], degradation and deadenylation [17,18].
Occasionally miRNAs can also up-regulate gene expres-
sion [19,20]. These small non-coding RNAs have been
implicated in a range of biological processes, including
cell growth, differentiation, apoptosis, and cholesterol
metabolism [15,21]. These processes are important for
the initiation and progression of atherosclerosis. Conse-
quently, dysregulation of miRNA function may lead to
atherosclerosis. For example, miR-365 is up-regulated by
ox-LDL-C, leading to reduced expression of BCL2, an
antiapoptotic gene, in arterial endothelial cells [22]. miR-
155 and miR-146a are associated with accumulation of
ox-LDL-C in monocytes [23,24]. It has been shown that
miR-92a controls angiogenesis of atherosclerotic plaques
in mice, leading to destabilization and rupture [25]. miR-
NAs, let-7 and miR-17-92 cluster, are known to target
thrombospondin-1, an inhibitor of angiogenesis [26].
Furthermore, miR-210, -15b, -16, and -20b are impli-
cated in down-regulation of vascular endothelial growth
factor [27-29], a key gene in cell migration in the athero-
sclerotic lesion. Studies also indicate that the up-
regulation of miR-335 and −122 is associated with lipid
metabolism in obese mice [30,31] and chimpanzee [32].
This suggests that expressed miRNAs play a fundamen-
tal role in dyslipidemia, a major risk factor for athero-
sclerosis. Importantly miRNAs have been shown to
exhibit temporal and spatial expression patterns, empha-
sizing the need to define cell–type–specific miRNA ex-
pression profiles, which require expression-sensitive
tools to capture low-abundance small RNAs.
Although the baboon is a well-characterized model for
human biomedical studies, including CVD, very little is
known about baboon (Papio hamadryas) miRNAs [16].Discovering liver miRNAs, identifying diet responsive
miRNAs that differ between low and high LDL-C
responders, and understanding how miRNAs regulate
gene expression in the baboon will provide insights on
the role of miRNAs in dyslipidemia. In this study, we
have used Next-Generation sequencing methods to per-
form deep sequencing of small RNA libraries derived
from liver biopsies collected before and after a HCHF
challenge diet from six half-sib baboons (low LDL-C,
n = 3; high LDL-C, n = 3), differing in their LDL-C re-
sponse to dietary fat and cholesterol. The sequence reads
were aligned to human genome; notably the current
draft of baboon genome is an unannotated draft assem-
bly which does not provide chromosomal coordinates or
transcript identification as with the human genome se-
quence. However, based on physical maps, the baboon
and human genomes exhibit considerable sequence con-
servation and synteny [33]. We identified differentially
expressed miRNAs in response to the challenge diet in
the two LDL-C phenotypes and used in-silico methods
to identify miRNA targets.
Results
Annotation of small RNAs and identification of novel
miRNA genes
Sequencing 12 baboon liver small RNA libraries yielded a
total of 2,765,191 sequence reads with an average
230,433 reads per sample ranging from 95,728 to 441,911
reads. A total of 770,816 unique tags mapped perfectly to
the human genome sequence, with an average of 64,235
tags per sample ranging from 38,701 to 138,915 tags. On
average 7% of the tags per sample were identical to
human miRNAs. Table 1 shows the number of clusters
generated, number of mapped unique tags per sample,
and the proportion of tags mapped to miRNA sequences
and their expression levels.
The small RNA libraries exhibited a diverse size distri-
bution of sequence reads that aligned to human genome
(Figure 1). Sequence reads (22nts) were the most abun-
dant in all sequenced libraries. The proportion of ex-
pression levels of small non-coding RNAs is shown in
Figure 2. miRNAs were the most abundantly expressed
small RNAs (mean= 62%) in libraries from low and high
LDL-C baboon livers (Figure 2a). Other small non-
coding RNAs such as small interfering RNAs (siRNAs),
small nucleolar RNAs (sno RNAs), small nuclear RNAs
(snRNAs), and transfer RNAs (tRNAs) comprised 27%
of the total expressed tags. Repeat-associated RNAs
accounted for only 3% of the tags. Unique tags that did
not map (“unclassified”) to any small non-coding RNA
databases or to the human genome comprised approxi-
mately 7% of the small non-coding RNAs expressed in
the baboon livers. Figure 2b and c show the distribu-
tion of expression levels of small RNAs detected in low
Table 1 Baboon liver small RNA libraries: number of

















6910 192,812 138,915 3 61
6265 338,750 43,778 4 48
8024 127,616 79,038 7 67
HCHF
6265 441,911 38,701 5 35
8024 210,084 41,087 6 63
6910 368,270 74,531 7 63
High LDL-C
Chow
8623 281,930 47,782 5 65
1X3817 171,740 50,363 8 68
1X4154 162,244 38,943 7 67
HCHF
8623 217,753 41,587 5 63
1X3817 95,728 78,928 7 65
1X4154 156,353 97,163 15 74
Average 230,433 64,235 7 62
Total 2,765,191 770,816
Figure 1 Frequencies and lengths of baboon sequence reads.
The proportion (%) of different lengths of sequence reads that
aligned to the human miRNAs. The number above each bar
indicates the total number of reads with corresponding size.
Figure 2 Frequency of small RNAs in a) combined low and high
LDL-C, b) High LDL-C only and c) Low LDL-C only liver samples.
The proportion of expressed baboon small RNAs identical to human:
i) miRNAs are shaded light blue, ii), other non-coding RNAs
(including snoRNAs, tRNAs, siRNAs, and snRNAs) are shaded red, iii)
repeat-associated RNA sequences are shaded yellow, and iv) coding
transcript-associated sequences are shaded green. The proportion of
mapped but unclassified sequences is shaded dark blue.
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of miRNAs expressed in the high LDL-C baboon livers
(67%) was higher than in low LDL-C (56%) (Figure. 2b
and c).
We discovered 517 miRNAs in baboon livers: 490
were identical to human miRNAs, herein referred to as
known miRNAs, and 27 novel baboon miRNAs (Table 2).
Each novel miRNA had a corresponding near comple-
mentary sequence, referred as miRNA star (miRNA*).
Table 3 shows the total numbers of known and novel
miRNAs detected from low and high LDL-C baboons on





Low LDL-C 33 5
High LDL-C 19 12




Table 4 miRNA expression categorized by diet for each
LDL-C phenotype
Identical baboon-human miRNAs Novel miRNAs
Low LDL-C
Chow only 37 4
HCHF only 14 3
Both diets 420 3
Total 471 10
High LDL-C
Chow only 16 5
HCHF only 34 7
Both diets 417 5
Total 467 17
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NAs was detected in the 12 samples ranging from 379
to 442 miRNAs per sample. A higher number of novel
miRNAs was identified in high LDL-C responders com-
pared to low LDL-C responders (low LDL-C, n = 20;
high LDL-C, n = 29). Further, we identified more novel
miRNAs in baboon livers from the HCHF challenge diet
than chow diet in high LDL-C responders. Table 4
shows the breakdown of miRNAs expressed in each ba-
boon phenotype in response to the two diets. In both ba-
boon phenotypes, the majority of known miRNAs (89%)
were not diet specific, while 11% of the miRNAs were
expressed only in response to a specific diet. The HCHF
diet elicited expression of more miRNAs in high LDL-C
responders than in low LDL-C responders (Fisher’s exact
test; p = 0.0001). In contrast low LDL-C responders
expressed more miRNAs on chow diet (p = 0.0001) than
the HCHF diet. Thus, miRNA expression is responsive
to diet and potentially associated with dyslipidemia in
baboons. Additional files 1 and 2 contain known and
novel miRNAs detected from all the liver samples.Table 3 Frequency of miRNA expression for each LDL-C









Chow HCHF Chow HCHF
High LDL-C
8623 409 425 7 8
4145 381 407 3 3
3817 379 387 4 4
Total 1169 1219 14 15
Average 390 406 5 5
Low LDL-C
6265 391 396 4 3
8024 383 379 1 2
6910 442 391 5 5
Total 1216 1166 10 10
Average 405 389 3 3Differential expression profiling of miRNAs responsive to
dietary fat
There was a statistical difference (Fisher’s exact test;
p < 0.05) between the number of miRNAs differentially
expressed in high LDL-C baboons in response to HCHF
diet (n= 18) compared to 10 miRNAs for low LDL-C
responders. Two miRNA families are shared between the
two baboon phenotypes. In this study miR-29 family
members were significantly down-regulated in response to
HCHF diet in both low and high LDL-C baboons. Inter-
estingly, the expression of some miRNA gene families
showed polycistronic regulation, such that a subset of
members of one family was either down-regulated in one
phenotype or up-regulated in another. For example, a sub-
set of miRNA let-7 family members was down-regulated
in low LDL-C baboons but up-regulated in high LDL-C
baboons (Additional file 1). In the Additional file 3: Table
S1 lists the miRNAs that were differentially expressed, p-
value, fold change and the complete mature miRNA
sequences.
Moreover, some miRNAs were strictly diet-specific;
these miRNAs, although not differentially expressed,
exhibited peculiar characteristics in which they were
expressed either in response to chow diet but not HCHF
diet, or vice versa (Additional file 3: Table S2). In
addition some miRNAs were polymorphic between low
and high LDL-C baboons. For example, miR-181c and
302a were expressed in low LDL-C baboon livers while
181a and 320b were detected in high LDL-C baboon
livers.
We observed that a substantial portion of sequence
tags perfectly mapped to other non-coding RNAs in-
cluding snoRNA, siRNA, snRNAs, and tRNAs in Rfam
database. These RNAs accounted for 20-33% of the total
expressed tags in the two phenotypic groups (Figures 2b
and c). Moreover, 31% (1,064/3,456) of other non-coding
RNAs in high LDL-C baboons were differentially
Table 6 Novel baboon miRNAs categorized by diet and
LDL-C. The numbers of predicted target genes, and the
2-7mer seed region for each novel miRNA, are shown
Chow diet
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ery Rate (FDR) ≤ 0.05) (Additional file 4). These small
RNAs were not differentially expressed in low LDL-C
baboon livers in response to the HCHF diet.High LDL-C Low LDL-C
‘Seed’ No. of targets ‘Seed’ No. of targets
GGGTGCG 37 ACCTCGA 6
TAAGAAC 423 TGGAATA 315
TGGACGT 8 TTATAAT 826
TTGACTA 111
Total unique targets 561 Total unique targets 1079
HCHF diet
High LDL-C Low LDL-C
‘Seed’ No. of targets ‘Seed’ No. of targets
CCCAAAT 306 TTCTGAT 441
CCCGCGG 6 TGGACGT 8





Total unique targets 902 Total unique targets 416
Both diets
High LDL-C Low LDL-C
‘Seed’ No. of targets ‘Seed’ No. of targets
ATCAAGG 147 ATCAAGG 147
CCGCCCT 14 CCGCCCT 14
TTTTTGC 349 CAGGCAC 402
CAGGCAC 402
TTGTTGC 179
Total unique targets 985 Total unique targets 552Targets of differentially expressed miRNAs in baboon
livers
miRNA target predictions indicate many-genes- to -many-
miRNAs regulation modules in which one miRNA has
multiple targets, and a protein coding gene has multiple
miRNA sites. A significantly higher number of targets
were predicted for miRNAs differentially expressed in
high LDL-C livers compared to low LDL-C livers (Fisher’s
exact test; p = 0.001) (Table 5). miRNAs common in both
baboon phenotypes accounted for 13% (2,931/22,598) of
the total human gene targets and about 80% (111/140)
of the experimentally validated targets. We found that
each differentially expressed miRNA family had on aver-
age 2,124 target genes ranging from 40 to 3,586. A sub-
stantial number of rhesus targets overlapped with those
in human genome. Because the currently available ba-
boon genome is an unannotated draft sequence we were
not able to perform comparative analyses with baboon
and rhesus and baboon and human genomes. Further-
more, the draft baboon genome sequence is not available
via the TargetScan software, Identified miRNA targets
included genes that have been implicated in risk factors
contributing to atherosclerosis. These targets include
protein coding genes involved in lipid metabolism, fatty
acid biosynthesis, and immune and inflammatory sys-
tems. We estimate that 9% (1,357/14,356) of the miRNA
targets comprise CVD-related genes in human and/or in
mouse.
Novel miRNAs expressed in high LDL-C livers, re-
gardless of diet, had a greater number of predicted target
genes (n = 2,448) than miRNAs expressed in low LDL-C
livers (n = 2,047) (Table 6). Of the 2,448 genes targeted
by novel miRNAs from high LDL-C livers, 99% (2,438/
2,448) are predicted to be targeted by known miRNAs
expressed in high LDL-C baboon livers. Interestingly,
80% (1,631/2047) of miRNA targets in low LDL-CTable 5 Number of predicted and validated gene targets
for the 28 differentially expressed miRNA families
Low LDL-C High LDL-C Common
miRNAs families differentially
expressed in response to
HCHF diet, p≤ 0.05
10 18 2
Human gene targets 9,764 12,834 2,931




Experimentally validated targets 16 124 111baboons are predicted to be regulated by miRNAs re-
sponsive to chow diet. These results suggest that liver-
expressed miRNAs in high LDL-C baboons potentially
target genes responsive to elevated LDL-C concentra-
tions while in low LDL-C responders, the majority of




High LDL-C is the major risk factor for atherosclerosis,
the leading cause of CVD. Underlying the pathogenesis
of atherosclerosis are complex networks of genes regu-
lated by a plethora of elements including miRNAs. In
this study we investigated differential expression of hep-
atic miRNAs in baboons differing in serum LDL-C con-
centrations in response to HCHF diet, and predicted
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metabolism and regulation of serum cholesterol includ-
ing LDL-C, and hepatic inflammation is associated with
early atherosclerosis [34]. To understand the liver micro-
RNAome relevant to LDL-C phenotype and dietary fat
and cholesterol, we performed high coverage Next-
Generation sequencing, annotated the baboon liver small
RNA transcriptome and quantified expression of small
RNAs. The baboon is a well-characterized model for
dyslipidemia and atherosclerosis [35,36], and is very
similar to humans both physiologically and genetically
[33]. In addition to genetic background, we are able to
control diet and environment in a nonhuman primate,
which is not feasible in humans. For this study, animals
exhibiting discordant LDL-C serum measures (low and
high LDL-C responders) were challenged for 7 weeks
with a HCHF diet. Liver samples were collected from six
half-sibs discordant for LDL-C before and after the chal-
lenge diet. By analyzing half-sib baboons discordant for
the quantitative trait (< 2 S.D. difference), we minimized
genetic variation due to genetic background and
increased the likelihood that we would discover miRNAs
that are diet responsive and that differ by LDL-C
phenotype.
Identification of baboon liver miRNAs
The distribution of non-coding RNA sequences identi-
fied in this study is in concordance with previous studies
identifying miRNAs using deep sequencing methods.
The length distribution of sequence reads indicates that
22-nt fragments were the most abundant (Figure 2), cor-
responding to the average size of mature miRNAs [37].
We identified various categories of small non-coding
RNAs from baboon liver samples and observed that
miRNAs were the most abundant (62%), (Figure 2a), in
concordance with previous studies [38,39].
Various methods were applied in the identification of
baboon miRNAs. The first study to identify baboon miR-
NAs employed a combined approach involving genomic
computation and microarray expression [16]. In our
present study, we identified 490 miRNAs identical to
human miRNAs. This number far exceeds the 227 liver
miRNAs identified by genomic computational predic-
tion. Moreover, the total number of expressed baboon
liver miRNAs identified by sequencing increased by 21%
that detected by microarray [16]. In addition we identi-
fied 27 novel baboon miRNAs with corresponding
complimentary (‘star’) sequences (Table 2). The presence
of star miRNAs is compelling evidence for the DICER-
like processing from a miRNA hairpin and stringency
measures applied in the analysis. The identified baboon
miRNAs will contribute to the species-specific miRNA
database. These results demonstrate the power of paral-
lel and high-throughput Next-Generation sequencing inelucidating differential expression profiles of miRNAs in
baboon livers.
Next Generation (NG) deep sequencing has become a
method of choice for discovering miRNA sequences and
expression. NG technology allows detection of low copy
number miRNAs in the transcriptome and discovery of
novel small RNAs, with excellent reproducibility [40].
Although QRT-PCR is the method of choice for validat-
ing array-based RNA expressions, it is a relative measure
of expression normalized against expression of a ‘house-
keeping’ gene. In contrast, expression profiling by deep
sequencing is normalized against the whole transcrip-
tome providing more robust data in a high coverage se-
quencing experiment than what can be attained by
QRT-PCR. For example, in this study the average read
counts for baboon liver small RNAs was approximately
800,000. Moreover, NG sequencing enables detection of
variation in mature miRNAs and RNA editing. Thus,
deep sequencing remains an extremely sensitive ap-
proach for identifying miRNA expression levels and for
detecting novel and variant miRNA sequences.
Expression of small non-coding RNAs
Expression profiling of non-coding RNAs in baboon
livers indicated that a subset of miRNAs is diet-specific,
potentially influencing LDL-C variation in baboons. A
significantly higher number of miRNAs were expressed
in response to HCHF challenge diet in high LDL-C
baboons than in low LDL-C baboons (Table 3). In
addition we have discovered miRNAs differentially
expressed in response to the HCHF diet and common in
both low and high LDL-C baboons (Figure 3).
Several expressed miRNAs in this study were previ-
ously reported to be involved in lipid metabolism and
CVD, including atherosclerosis (Table 7). For example,
miR-122, which is highly abundant in liver, is associated
with serum cholesterol levels in mice and primates
[30,32]. miR-221 and miR-222, which share an identical
seed region, are associated with arterial smooth muscle
angiogenesis [41]. Moreover, down-regulation of miR-
155 and -146a is associated with enhanced accumulation
of oxidized LDL-C in monocytes [23], potentiating in-
flammation of the intima layer of arteries and generation
of atherosclerotic lesions. Further, increased expression
of miR-335 is associated with elevated lipid metabolism
in obese mice [31]. Our results show that miR-122 is
up-regulated in response to the HCHF challenge diet in
low LDL-C but down-regulated in high LDL-C baboons.
miR-221 and miR-222 were significantly down-regulated
in response to HCHF diet in both low and high LDL-C
baboons. miR-155 and -146a were down-regulated in re-
sponse to the HCHF diet in our study. Further we
observed that miR-335 is up-regulated in low LDL-C
baboons but is not expressed in high LDL-C animals.
Low LDL-C High LDL-C 
Figure 3 Families of baboon liver differentially expressed
miRNAs. The Venn diagram includes both up- and down-regulated
miRNAs (p≤ 0.05) in low and high LDL-C baboon responders in
response to the HCHF diet challenge.
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be dependent on the threshold level of serum choles-
terol. This observation is consistent with results by
Maxwell et al. [42], which indicate that reduced serum
cholesterol levels may trigger expression of some genes
involved in lipid metabolism. Altogether, the results
from the sequence data indicate we were able to capture
some of the potential miRNA candidates encoding risk
factors related to atherosclerosis.
Although miR-33a/b were not differentially expressed
in response to the HCHF challenge diet both miRNAs
were detected in low and high LDL-C livers, however, at
differing amplitudes. miR-33a was more abundant in low
LDL-C while miR-33b was more abundant in high LDL-
C livers. These findings are consistent with previous
studies that indicate miR-33a is highly expressed in low
sterol condition whereas miR-33b is more abundant in
cholesterol-filled cells [50]. miR-33 family is transcribed
from the introns of sterol-regulatory element-binding
factor (SREBF) isoforms and is linked to cholesterol
homeostasis [51].
In this study, we identified differentially expressed
miRNAs that are predominantly engulfed by HDL parti-
cles [52]. miR-877 and 191 were differentially expressed
in low and high LDL-C livers, respectively. The results
are consistent with findings by Vickers and colleagues,
indicating that miR-877 is abundantly expressed innormal individuals while miR-191 is up-regulated in fa-
milial hypercholesterolemia (FH) human subjects. Muta-
tion in LDL receptor (LDLR) leads to FH and severe
development of atherosclerotic lesions in homozygous
individuals [53]. In addition we found that miR-19 was
differentially expressed in high LDL-C baboons and not
in low LDL-C responders. miR-19 is abundant in LDLR
mutant mice [52]. Together, these findings indicate that
these miRNAs are potentially involved in regulation of
dyslipidemia and HDL particles may be involved in their
transport to recipient cells as an anti-atherogenic
mechanism.
During the biogenesis of miRNAs, a duplex RNA is
generated [15]. Only a single strand (mature miRNA) is
loaded into RNA-induced silencing complex (RISC)
while a near complementary strand, miRNA star
(miRNA*), is degraded [54,55]. Recent studies based on
deep sequencing have uncovered the presence of
miRNA* in different systems but in low abundance [38].
This indicates the power of deep sequencing in detecting
low copy number miRNAs previously thought to be
degraded. In our study we confirmed presence of miR-
NAs* (Additional file 1). In addition we discovered that
some miRNAs* exhibit higher expression than the ma-
ture miRNAs, are inversely regulated between low and
high LDL-C responders, or are detected in some samples
where mature miRNAs are absent. For example, miR-
222* was up-regulated in response to HCHF diet in low
LDL-C baboon livers but down-regulated in high LDL-C
responders while mature sequences were down-regulated
in both LDL-C phenotypes. These observations indicate
that processing of miRNAs is regulated and that regula-
tion of processing can affect gene expressions.
Although miRNA families have a consensus 5’ end
‘seed’ region, little is reported on upstream polymorph-
isms, which may affect the binding efficiency of the
miRNA on mRNA UTRs, in relation to the phenotype of
interest. In this study we identified some miRNAs that
have nucleotide polymorphisms between low and high
LDL-C responders including miR-181 and 302. miR-181
variants have identical ‘seed’ region; however, variant
181a has a G allele insertion flanking the 8-mer seed re-
gion in comparison to 181c. miR-181 has a consensus
binding site in humans, chimpanzee and rhesus macaque
but not mice and rats. In comparison, 302a and c have
G/A substitutions at the 3’ end, contributing to differing
total context scores and binding efficiency. Mice, rats,
rhesus macaque, chimpanzee and humans have a con-
sensus binding sequence for miR-302. In contrast rabbits,
which are often used to model dyslipidemia and athero-
sclerosis do not have sites for miR-181 or 302 [56].
Furthermore, differentially expressed miRNAs in ba-
boon livers (Figure 3) have been implicated to have
multiple roles in different types of diseases. For example
Table 7 Expression profiles of miRNAs associated with metabolic disorder risk factors
miRNA Low LDL-C
(Chow vs HCHF)
p value High LDL-C
(Chow vs HCHF)
p value Biological processes associated with
disease risk factors
References
miR-29b Down 0.018 Down 0.01 Demethylation of MMP-2/MMP-9 genes
involved in cell migration in aorta
[43]
miR-26a-1* Down 0.007 Down 0.32 Regulator of vascular smooth muscle cell function [44]
miR-221 Down 0.45 Down 0.02 Angiogenesis in hypertrophy [41]
miR-222 Down 0.39 Down 0.01 Angiogenesis in hypertrophy [41]
miR-222* Up 0.98 Down 0.66
miR-143 Down 0.67 Down 0.17 Proliferation of vascular smooth muscle cells [45]
miR-122 Up 0.69 Down 0.19 Lipid metabolism [30,32]
miR-122* Down 0.43 Down 0.38
miR-335 Up 0.48 - - Lipid metabolism [31]
miR-335* Down 0.31 Down 0.29
miR-21 Down 0.63 Down 0.62 Cell proliferation in carotid artery [46]
miR-1 Down 0.42 Down 0.35 Repolarization and diastolic activity [47]
miR-146a,b Down 0.12 Down 0.36 LDL-C oxidization accumulation in monocytes [23][24]
miR-155 Down 0.17 Down 0.43 Oxidized LDL-C accumulation in monocytes [24]
miR-130b Down 0.98 Down 0.59 Arteriosclerosis obliterans [48]
miR10a Down 0.39 Down 0.47 Regulation of pro-inflammation in aorta [49]
- Indicates that the miRNA was not detected. miRNA stars (*) are presented for comparison with mature miRNAs.
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down-regulated in prostate cancer [58] and up-regulated
in rheumatoid arthritis [59]. Down-regulation of miR-34b
is associated with tumorogenesis suppression [60]
and Parkinson’s disease [61] and its suppression via
methylation confers anti-apoptotic effects on colorectal
cancer [62]. miR-34b targets include TENC1 (tensin
like C1 domain containing phosphatase), which has
been implicated in apoptotic events in vitro [63]. These
observations suggest that miRNAs have different roles in
distinct tissues and that the effects on gene expression
should be interpreted in the context of cell state.
Our results indicate that a significant proportion of
expressed small non-coding RNAs include other
miRNA-sized small non-coding RNAs such as snoRNAs,
siRNAs, snRNAs and tRNAs. Non-coding RNAs
(n = 3,455) were expressed in high LDL-C responders
while 4,645 were identified in low LDL-C livers. We
observed that 31% (1,064/3,455) of other non-coding
RNAs in high LDL-C baboons were differentially
expressed (FDR ≤ 0.05) in response to HCHF diet. Non-
coding RNAs were not differentially expressed in low
LDL-C baboons. A total of 2,277 RNAs were expressed
in both baboon phenotypes including 99% of those dif-
ferentially expressed in high LDL-C livers. The func-
tional role of these small RNAs in dyslipidemia is not
clear. However, prior reports indicate that deep sequen-
cing generates a considerable number of sequence tags
perfectly mapping to other known small non-coding
RNAs [64]. At least one study [65] identified snoRNAswith miRNA-like function and DICER processing signa-
tures. It is plausible these RNAs may have functional
roles in dyslipidemia.
miRNAs are often expressed in gene clusters, and their
transcription is thought to be closely linked [16,66]. In
this study we observed that miRNA clusters and cluster
members were coordinately regulated. For example, the
majority of let-7 family members are down-regulated in
low LDL-C responders but up-regulated in high LDL-C
responders. However, not all members of the family
exhibited a coordinated pattern, suggesting an independ-
ent regulation event. A recent study [38] confirmed that
some miRNAs show differential expression in distinct
cells due to post-transcriptional regulation associated
with variation in the levels of DICER, an enzyme
involved in biosynthesis of mature miRNA. It is plausible
that the expressions of some let-7 cluster members are
dependent on cell context or independent of cluster
transcription unit. Recent studies have uncovered the as-
sociation of clustered miRNAs and complex diseases in-
cluding B-cell leukemia [67,68] and testicular carcinoma
[69-71]. These miRNA clusters tend to occur in fragile
regions of genomes and may be species-specific
[16,72,73].
miRNA gene targets and atherosclerosis
Many of the predicted targets of expressed miRNA
family members, with identical seed regions, overlapped
considerably. Thus, it is logical to focus on identical
seed regions or the miRNA family names when
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seed region are classified as one family. In this study,
we sought to identify genes targeted by expressed
miRNA families in low and high LDL-C baboons using
in silico methods.
For differentially expressed miRNAs responsive to the
HCHF diet, we observed a substantial (> 90%) overlap
between targets identified in human and rhesus macaque
genomes (Table 5). Because the genome assembly of ba-
boon is in draft form, we used the rhesus genome to
identify predicted gene targets. Baboon is closely related
to rhesus macaque with 98% sequence identity [74]. This
conservation of a large percentage of miRNA target sites
between human and rhesus and the high sequence iden-
tity between rhesus and baboon suggests that our find-
ings in baboons may translate to humans given that our
data constitute sequences that are identical between
human and baboon genomes. Nonetheless, a recent
study [75] has shown that evolutionary changes in
miRNA binding sites, may inhibit or enhance the effect
of miRNAs on gene expression regulation. The study by
Richardson et al. revealed that the PLIN4 3’ UTR has
undergone nucleotide substitution allowing the binding
of miR-522 for human individuals with A but not G al-
lele. The miR-522 binding site with A allele was not
found in Neanderthal and non-human primates suggest-
ing a recent evolutionally change. Until an annotated ba-
boon genome sequence is available we will not be able
to assess conservation of miRNA targets sites between
baboon and human and baboon and rhesus.
In this study, we observed many-genes-to-many-miR-
NAs regulation modules, suggesting that many genes are
coordinately and cooperatively regulated by miRNAs.
Genes targeted by multiple miRNAs are tightly regulated
and may show graded expression in response to expres-
sion of different miRNAs. In addition, genes tightly
regulated by redundant miRNAs may be an indication of
their central role in the cell. We observed that, on aver-
age, about 2,000 genes are targeted by a single miRNA
family, which presents daunting challenges for the devel-
opment of a pharmaceutical agent with specific target.
Moreover miRNA target prediction revealed that some
genes are cooperatively targeted by miRNAs differing in
their response to HCHF diet; i.e., one miRNA was up-
regulated while the other was down-regulated in re-
sponse to the HCHF diet, but both miRNAs have the
same target. For example, LDLRAP1 (low density lipo-
protein receptor adapter protein 1, which interacts with
LDL-C receptor) is targeted by miR-27a and -26a that
are up- and down-regulated, respectively, in response to
the HCHF diet. The molecular interactions of these
miRNAs with LDLRAP1 are not known, but it is plaus-
ible this phenomenon may be an inherent mechanism to
balance gene expression levels. miR-27a and 26a aredifferentially regulated and implicated in adipogenesis
[76,77].
We estimate that differentially expressed miRNAs in
our study targeted 9% of the total genes implicated in
atherosclerosis [78,79]. The following miRNA targets are
included among those potentially associated with athero-
sclerosis: 1) LDLR, a cell surface protein involved in
receptor-mediated endocytosis of LDL-C. Mutations in
this gene cause the autosomal dominant disorder famil-
ial hypercholesterolemia [80] and increased carotid ar-
tery intima-media thickness [81]. 2) VLDLR (very low
density lipoprotein receptor) plays important roles in
VLDL triglyceride metabolism [82]. 3) LIPA (lipase A
precursor) catalyzes the hydrolysis of cholesterol esters
and triglycerides in lysosomes, and mutations in the
gene is associated with impaired endothelial function in
CVD [83]. Other targets of interests include PTEN
(phosphatase and tensin homolog), which functions as a
tumor suppressor by negatively regulating intracellular
levels of phosphatidylinositol-3,4,5-trisphosphate, sub-
strates for AKT (tyrosine kinase B protein) in the intra-
cellular AKT/PKB signaling pathway, and TENC1
(tensin-like C1 domain containing phosphatase), which
is thought to act in a similar manner as PTEN in depriv-
ing substrates for AKT [84]. Further, we observed that
ACVR1B (activin A receptor, type IB isoform c precur-
sor) is considerably targeted by both novel and known
miRNAs. ACVR1B is well-conserved in primates in-
cluding human, rhesus, and orangutan, but relatively
less-conserved in chimpanzee. ACVR1B is a receptor for
activin growth factor, which belongs to TGF-beta (trans-
forming growth factor-beta) superfamily. TGF-beta is
involved and implicated in inflammatory processes, such
as atherosclerosis in arteries [85]. Altogether this study
identifies potential atherogenic candidate genes, targeted
by differentially expressed baboon miRNAs. Identifying
the roles of miRNAs and their target genes and signaling
pathways in atherosclerosis will be critical for future re-
search. miRNAs represent new regulatory factors for
cardiovascular biology and are an emerging novel class
of therapeutic targets for CVD.
Although identification of miRNA gene targets is a key
step in elucidating miRNA functional mechanisms, com-
prehensive identification of targets still presents a daunt-
ing challenge. There are many bioinformatics tools
available to predict miRNA targets; however, consistency
among different platforms is limited [86]. In this study,
we employed TargetScan, which is the most widely used
tool in target prediction [87]. Because of the limitation
of the high-throughput in-silico prediction, experimental
validations of the miRNA-mRNA interaction are neces-
sary. The experiments include reporter gene assay and
loss- or gain-of-function of miRNA to measure target re-
pression. However, these validation experiments are
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dated miRNA targets. For example, our results generated
using IPA indicate only 1% of the total miRNA targets
have been validated. Recently, a high-throughput and
sensitive technique for identification and quantification
of miRNA targets has been reported [88]. The technique
involves in-situ co-immunoprecipitation of mRNA asso-
ciated with RISC, loaded with a specific miRNA, and
subsequent deep sequencing. The technique, RISC-Seq,
is a modification of a previous approach that utilized
microarray profiling [89] and has been further optimized
[90]. There is no doubt the technique provides import-
ant insight into determining the full spectrum of
miRNA-mRNA interactions. However, the method is not
yet fully optimized, and the modifications suggested by
Matkovich et al. [90] present challenges due to over-
expression of Argonaute2 protein in RISC complex,
which may induce out-of-context cell state. Second, the
technique does not address all outcomes of functions of
miRNAs; a substantial number of miRNAs act by silen-
cing the translation machinery and epigenetic modifica-
tions. Thus, until the RISC-Seq approach is fully
optimized, in-silico prediction and basic experimental
validations will remain useful approaches in deciphering
the miRNA-mRNA interactions.Table 8 The mean (mg/dL) and standard deviation of the
LDL-C levels in low and high LDL-C baboons on chow and
HCHF diets
Diet Chow HCHF
High LDL-C Responders 43.7 (15.01) 114.3 (19.5)
Low LDL-C Responders 19.3 (8.1) 31.3 (2.5)
Standard deviations are indicated in parenthesis.Conclusion
We have sequenced baboon liver small RNA samples
from half-sibs discordant for serum LDL-C and were
fed chow and HCHF diets. We identified 517 baboon
miRNAs including 490 that are identical to human and
27 novel miRNAs. The list of miRNAs reported in this
study will contribute to the public database for small
RNAs. Further, we identified 30 differentially expressed
miRNAs in response to a HCHF challenge diet in two
distinct baboon phenotypes previously characterized for
extreme responses to dietary fat. Six of these differen-
tially expressed miRNAs have been previously identified
as regulators of genes that play roles in CVD. We also
identified miRNA variants and other non-coding RNAs
differentially expressed in response to the HCHF diet.
Analysis of target genes of the differentially expressed
miRNAs showed that 9% of the currently annotated
CVD-related genes are predicted to be regulated by
these miRNAs. Future studies that include gene se-
quencing in these samples to identify all expressed
genes and gene variants in combination with gene/
miRNA interactions in these LDL-C responders will
take us closer to understanding the genetic and epigen-
etic networks that underlie LDL-C response to dietary
fat and cholesterol, thus providing potential central
genetic targets for miRNA-based therapeutic agents to
regulate LDL-C.Methods
Animals
Baboons (Papio hamadryas) were maintained by the
Southwest National Primate Research Center (SNPRC)
at the Texas Biomedical Research Institute (Texas
Biomed), which is accredited by the Association for As-
sessment and Accreditation of Laboratory Animal Care
International. Experimental protocols were approved by
the Institutional Animal Care and Use Committee and
were conducted under the supervision of Southwest Na-
tional Primate Research Center staff veterinarians.
Selection of baboon sib-pairs discordant for LDL-C
Based on phenotypic and genotypic analysis of 951 pedi-
greed baboons, we identified three half-sib-pairs with
contrasting phenotypes for LDL-C as described [91].
The sib-pairs differed by at least two standard deviations
for LDL-C serum concentrations. In addition, members
of each selected sibling pair were discordant for at least
1 marker loci within the support interval for an LDL-C
QTL on baboon chromosome 4 [92].
High-cholesterol, high-fat (HCHF) dietary challenge
The dietary challenge protocol has been described else-
where [93,94]. Briefly, liver biopsies were collected from
the half-sib animals at baseline while consuming a basal
diet (chow) low in fat (4% of calories) and cholesterol
(0.03 mg/kcal). The animals were then fed the HCHF
diet, high in fat (40% of calories) and cholesterol
(1.7 mg/kcal), for 7 weeks, and liver biopsies were col-
lected. Tissue samples were snap-frozen in liquid nitro-
gen and stored at −80°C. Table 8 shows the mean and
standard deviation of the LDL-C levels in low and high
LDL-C baboons on chow and HCHF diets.
Liver biopsy collection
Baboons were sedated with ketamine (10 mg/kg), given
atropine (0.025 mg/kg) and intubated. Anesthesia was
induced and maintained with isoflurane (1-2%). Blood
pressure was measured by automated arm cuff (Collin)
and oxygen saturation, heart rate, and respiration were
monitored by pulse oximetry. Biopsies were collected
from the left lobe of the liver using Temno Evolution
Needle, gauge 14 (CareFusion, San Diego, CA). During
post biopsy recovery analgesia was provided in the form
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25 mg/day for 10 days.
Small RNA library preparation
miRNA-enriched fractions were isolated from 10 mg of
baboon liver (n = 12) using the mirVanaTM miRNA Isola-
tion Kit (Ambion) according to the manufacturer’s
protocol and stored at −80°C until further use. Small
RNA libraries were prepared from the enriched fractions
with Illumina Small RNA Prep Kit v1.5 following
the manufacturer’s instructions. Briefly, the Illumina
3’ adapter (5’-ATCTCGTATGCCGTCTTCTGCTTGT)
was ligated to 2 μg of enriched small RNAs using T4
RNA truncated ligase (New England BioLabs) and 15%
PEG at 22°C for 2 hrs. Then, the Illumina 5’ adapter (5’-
GTTCAGAGTTCTACAGTCCGACGATC) was ligated
onto the 3’ adapter-linked RNA using T4 RNA ligase (New
England BioLabs) for 1 hr at 20°C. The 5’ and 3’ adapter-
linked RNA was converted to a single-stranded cDNA using
SuperScript II Reverse Transcriptase (Invitrogen) and Illu-
mina’s RT-Primer (5’-CAAGCAGAAGACGGCATACGA)
following the manufacturer’s protocol. The cDNA was
PCR-amplified with Hotstart Phusion DNA Polymerase
using the following profile: denaturation at 98°C for 30s,
15 cycles of 98°C for 10s, 60°C for 30s, 72°C for 15 s,
and a final extension at 72°C for 10 min.
The PCR product was purified on a 6% TBE urea poly-
acrylamide gel (Invitrogen). The gel was stained with
ethidium bromide and visualized under UV light. The
gel band corresponding to 93–100 bp was excised,
passed through a bottom-perforated 0.5 ml tube and
eluted in 1X Elution Buffer following the manufacturer’s
protocol. Notably, while the average length of a miRNA
is 22 nucleotides (nts), the excised band corresponds to
the total length of the adapter-ligated miRNAs. The
resulting gel slurry was spun in a Spin-X filter and RNA
precipitated with 2ul of glycogen, 10ul of 3 M-
ammonium acetate and 325 μl of 100% cold ethanol.
The mixture was centrifuged, and the resulting pellet
washed with 70% ethanol. The dried RNA pellet was
suspended in 10 μl of Resuspension Buffer (Illumina).
Next generation sequencing of small RNAs
Small RNA sequencing was performed using Illumina’s
Genome Analyzer (GAIIx). Diluted cDNA (10 nmol/L)
was amplified, sequenced, and single-read clusters gener-
ated using cBot Cluster Generation Kit and TruSeq SBS
Kit v5 (36 cycles). For the control sample, we used PhiX
Control Kit v3 (Illumina).
Analysis of sequence reads
Reads filtering and adapter trimming
miRNA sequence reads were analyzed using mirTools
[95], an interactive web-based tool for analyzing deepsequencing reads. Briefly, the small RNA sequence reads
were filtered to exclude low-quality reads and 3’/5’
adapter- and polyA-sequences. The reads were trimmed
off the 3’ adapter sequences using a custom perl script.
The resulting clean full-length reads were formatted into
a non-redundant FASTA file. Each sequence tag in the
file contains the number of reads represented by the tag.
Small RNA annotation
The resulting sequence tags (18–30 nts) were mapped
onto the human genome sequence (hg18) using the
SOAP2 program [96] embedded in mirTools. Subse-
quently, the reads were aligned against various databases
including miRBase [97], Rfam [98], RepeatMasker [99],
and the reference genome transcriptome database. Con-
sequently the sequence tags were classified as a known
miRNA, a degraded fragment from non-coding RNA, or
RNA derived from repeat or coding sequences.
Sequences that did not conform to any of the categories
but mapped to a unique location on the human genome
were termed “unclassified.”
Discovery of novel miRNAs
The prediction of novel miRNAs was performed by miR-
Deep software [54] and associated RNAfold software
[100], incorporated in mirTools using default settings.
Unclassified tags were used to predict candidate novel
miRNAs. Using RNAfold software, a sequence fragment
containing 100 nts flanking each side of the locus align-
ing to an unclassified tag was excised from the genome
sequence. RNAfold software folds and performs compu-
tational assessment of the fragment to ensure that there
is a minimum of 14 base pairings between the mature
and star sequences of the hairpin. Because false positive
hairpins can be formed from different types of small
RNAs in the genome, miRDeep software performs fur-
ther stringent analysis to test whether reads aligning to a
potential miRNA precursor (pre-miRNA) are consistent
with the Dicer processing signature to simulate miRNA
biogenesis in the cell; presence of 2-nt 3’ overhangs and
positional alignment of the reads on mature, star, or loop
of the precursor sequence. Extracted sequences that do
not have a Dicer signature and fold into a hairpin were
discarded. An unclassified sequence tag is considered
novel miRNA if it aligns to a candidate pre-miRNA.
Sequences with dominantly abundant reads were
denoted as mature miRNA and its complementary se-
quence as miRNA*.
Detection of differential expression of small RNAs
miRNAs and other non-coding RNAs differentially
expressed between chow and HCHF samples were deter-
mined by assessing the read counts as described [95]. A
sequence tag consists of one or more reads, which
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hence the expression level. We normalized an expression
level of a sequence tag, within and between samples,
by dividing the absolute read count by the total read
count of the sample and multiplied by 1,000,000. The
normalized count corresponds to the relative expression
level of each tag. Normalized expression data generated
from animals on chow and challenge diets were used to
determine differential expression levels in each pheno-
type. A two-tailed student t-test was performed to test
for significant expression levels for miRNAs expressed
on both diets and Welch’s t-test, assuming unequal vari-
ance, was performed for miRNAs with expression
detected in only one of the two groups. A small non-
coding RNA was considered differentially expressed be-
tween samples when the p-value was ≤ 0.05, and multiple
testing adjustments applied, where appropriate, using
False Discovery Rate [101].Target prediction
We identified potential targets of diet responsive differ-
entially expressed miRNAs in low LDL-C and high LDL-
C responders using TargetScan/Base Release 5.1 (http://
www.targetscan.org/) and Ingenuity Pathway Analysis
(http://www.ingenuity.com) tools. We identified novel
miRNA targets using TargetScan [102], employing the 7-
mer seed-region of each miRNA sequence to customize
prediction of targets.Additional files
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